Viking Therapeutics: Stock at $38.71 – Analysts See Price Target of $93.60

Viking Therapeutics Inc. (VKTX) closed at $38.71 on July 6, 2026, representing a gain of 3.39% from the previous close of $37.44. Trading volume was 48,782 shares. The daily range showed a span between $37.10 (low and open) and $38.87 (high).

Analyst Ratings Signal Upside Potential

Analyst consensus for Viking Therapeutics is positive: Of 24 tracked analysts, 22 assign a "Buy" rating, one recommends "Strong Buy," while only one remains at "Hold." No sell recommendations are present (as of July 6, 2026).

The average analyst price target is $93.60, with a median of $95.00. The range of estimates spans from $83.00 (lowest target) to $101.00 (highest target). Analysts thus see upside potential of approximately 142% compared to the current price.

Pipeline Focused on Metabolic and Endocrine Disorders

Viking Therapeutics positions itself as a clinical-stage biotech company focused on novel treatments for metabolic and endocrine disorders. The company is in the clinical development phase and has multiple product candidates:

• VK2809: An orally administered, tissue- and receptor-selective agonist of the thyroid hormone receptor beta (TRβ). The compound is currently undergoing Phase IIb studies for non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients as well as for non-alcoholic fatty liver disease (NAFLD).
• VK5211: An oral, non-steroidal selective androgen receptor modulator (SARM) in Phase II studies, being developed for patients recovering from non-elective hip fractures.
• VK0612: An oral drug candidate for Type 2 diabetes, intended for Phase IIb studies.
• VK0214: Another oral development candidate in the company's pipeline.

Technical Indicators Show Positive Momentum Development

The Relative Strength Index (RSI) for Viking Therapeutics was at 64.84 points on July 2, 2026. In the preceding days, the RSI moved between 60 and 75 points (period June 22–29, 2026), indicating a phase of rising momentum. An RSI above 70 is technically considered overbought; values in late June reached this area at times (75.36 on June 29, 75.03 on June 24).

Classification for Investors in the DACH Region

Viking Therapeutics is traded in US dollars. For investors from Switzerland, Germany, and Austria, this entails currency risk: fluctuations in the USD/CHF or USD/EUR exchange rate can affect returns. At a current price of $38.71, this corresponds to approximately 34.45 CHF (at an exchange rate of around 0.89) or 36.39 EUR (at 0.94).

The company is still in the clinical phase and generates no product revenues to date. Investments in biotech companies at this development stage are considered speculative, as success depends on clinical trial results, regulatory approvals, and subsequent market penetration. Positive analyst sentiment reflects expectations that at least one of the pipeline candidates could be successful.

Market Capitalization and Trading Liquidity

According to available data, the average trading volume for Viking Therapeutics is not provided, which complicates assessment of liquidity. On July 6, 2026, 48,782 shares were traded – a moderate volume that should provide sufficient trading opportunities for retail investors, though caution is warranted for larger positions.

The stock is traded on US exchanges. Investors in the DACH region can trade VKTX through international brokers, but should note trading hours (US exchanges open at 15:30 CET) and possible additional costs for US trading.